ReviewVirulence2025
Emergence, function, and therapeutic strategies to target the PD-1/PD-L1 immune checkpoint during pathogenic fungal infections.
Review in Virulence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human pathogenic fungi are ubiquitous in the environment and induce an expanding repertoire of devastating diseases globally. Upon fungal invasion, the fungus adopts multiple strategies to adapt to, or eliminate, hostile environmental conditions, which immune checkpoints serve as one of the mechanism for fungal evasion. Programmed death receptor-1 (PD-1), an immunosuppressive molecule, transmits inhibitory signals upon binding to its ligand PD-L1. During infection, aberrant activation of the PD-1/PD-L1 pathway has been proven to facilitate immune evasion by the pathogen. In this review, we summarize the roles of PD-1/PD-L1 in fungal infection. First, the molecular structures and function of PD-1 and PD-L1 are described. Then, we highlight the dynamic expression patterns and regulatory mechanisms of PD-1/PD-L1 during fungal invasion. Potential therapeutics based on PD-1/PD-L1-blocking to enhance antifungal immunity and improve clinical outcomes are also discussed. These insights reveal future directions regarding PD-1/PD-L1 and immune checkpoint-based therapies for preventing pathogenic fungi infections.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.